Question

A 62-year-old man with HFrEF (LVEF 30%) on bisoprolol, sacubitril/valsartan, and spironolactone remains symptomatic (NYHA II). He has diabetes but no CKD (eGFR 70 mL/min/1.73 m²). Which addition provides proven morbidity and mortality benefit?

Accepted Answer

Dapagliflozin

Answer

Ivabradine

Answer

Hydralazine alone

Answer

Loop diuretic uptitration

Answer

Digoxin

Practice question

A 62-year-old man with HFrEF (LVEF 30%) on bisoprolol, sacubitril/valsartan, and spironolactone remains symptomatic (NYHA II). He has diabetes but no CKD (eGFR 70 mL/min/1.73 m²). Which addition provides proven morbidity and mortality benefit?